Lorcaserin treatment decreases body weight and improves cardiometabolic risk factors of obese adults: A 6-month-long, randomized, placebo-controlled, double-blind clinical trial.

Lorcaserin is a serotonin 2c receptor agonist, which promotes weight loss while improving type 2 diabetes and atherogenic lipid profile without higher rates of major cardiovascular events. The full spectrum of the possible lorcaserin-induced cardiometabolic improvements remains to be clarified. Thus...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Diabetes Obes Metab
Hlavní autoři: Tuccinardi, Dario, Farr, Olivia M., Upadhyay, Jagriti, Oussaada, Sabrina M., Mathew, Hannah, Paschou, Stavroula A., Perakakis, Nikolaos, Koniaris, Anastasia, Kelesidis, Theodoros, Mantzoros, Christos S.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2019
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6504613/
https://ncbi.nlm.nih.gov/pubmed/30724455
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13655
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky